Whittier Trust’s Iovance Biotherapeutics IOVA Stock Holding History

Whittier Trust’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-56	Closed	-$1K	–	1720
2022 Q1	$1K	Buy	+56	New	+$866	﹤0.01%	1638

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Whittier Trust's IOVA Position: Q2 2022 in Review

Whittier Trust sold out of Iovance Biotherapeutics (IOVA) in Q2 2022, closing a stake of 56 shares — an estimated $1K sold.

Whittier Trust first reported a position in IOVA in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 237 funds tracked by Wall St. Rank hold IOVA as of Q2 2022.

Whittier Trust reported no remaining Iovance Biotherapeutics position as of Q2 2022 after selling out during the quarter.
Whittier Trust sold 56 Iovance Biotherapeutics shares in Q2 2022, an estimated $1K.
Whittier Trust first reported a position in Iovance Biotherapeutics in Q1 2022 and held it in 1 quarter.
Whittier Trust's Iovance Biotherapeutics position peaked at $1K in Q1 2022.
237 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2022.

Based on Whittier Trust's 13F filing for Q2 2022, filed 28 Jul 2022.